About us

●Dr. Faming Zhang defined the medical history of FMT in “American Journal of Gastroenterology”, and coined the Chinese name of ``fecal microbiota transplantation`` in CHINA JOURNAL OF ENDOSCOPY; The first clinical trial of FMT in China was registered by us.

●We invented the first automatic microbiota purification system GenFMTer (FMT Medical, Nanjing, China); Sponsored the 1st National Conference on Intestinal Disease and Fecal Microbiota Transplantation. Dr. Bota Cui et al. reported that FMT is effective in treating Crohn's disease-related abdominal pain, as well as other findings; Faming Zhang conceived and started to study Cap-assisted Endoscopic Sclerotherapy (CAES) for hemorrhoids and rectal prolapse.

●The journal Gut Microbes invited Dr. Faming Zhang to review the step-up FMT strategy; We sponsored the 3rd China Academic Conference on Integrated Bowel Disease; Published best-selling medical popular book entitled INTESTINE IN PERIL; Built GMP Laboratory for FMT in Sir Run Run Hospital, Nanjing Medical University; Invented mini-FMT and started multi-center clinical research.NATURE's annual review highlighted our report on the medical history of FMT; Dr. Faming Zhang gavea lecture at the World Life Science Conference and wrote the article entitled ``fecal microbiota transplantation system``; Dr. Xingyin Liu was selected as the distinctive medical talent in Jiangsu Province; Dr. Faming Zhang, Dr. Xingyin Liu, and Dr. Bota Cui gained fundings from the National Natural Science Foundation of China.

●We co-sponsored the 2018 China Gut Festival with 2500+ participants at the China National Convention Centerin Beijing. Dr. Faming Zhang lead the FMT-standardization Study Group and published a cover paper in Protein&Cell; Dr. Chuyan Long et al. reported the first research results on the technique of a novel quick transendoscopic enteral tubing in mid-gut; Dr. PanLiet al. first time reported the timing for the second FMT to maintain the long-term benefit from the first treatment for Crohn’s disease; Dr. Honggang Wang et al. first time reported that GenFMTer reduced the adverse events of FMT but did not affect the efficacy.

We first time demonstrated that WMT is safe and effective to improve intestinal symptoms and mucosal injury in patients with chronic radiation enteritis. Our latest findings indicate that it is important to understand the efficacy of WMT in Crohn’s disease as a targeted therapy, especially for abdominal pain, hematochezia, fever and diarrhea.

Collaboration with Zhang Yan's team led to the first report in Environ Sci Technol, showcasing how microplastics promote the progression of IBD;A 10-year research endeavor was published in the journal ``Microb Biotechnol``, presenting the development of CMTS;The effective control of amyotrophic lateral sclerosis (ALS) by WMT was first reported in J Biomed Res;In Chin Med J, it was stated that WMT and TET are the core advancements in the global field of fecal microbiota transplantation;The first national standard for WMT in China, led by our team, was officially released and implemented;The establishment of the Human Microbiota Salon facilitated the exchange and development of microbiome medicine;The construction of a world-renowned laboratory in the field of microbiome diagnosis and treatment technology was completed;The related invention technologies entered a new stage in LBP.